Everything below concerns LC-MS/MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-02. Numbers and descriptions here follow the published literature rather than marketing material.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in dimethyl sulfoxide and some organic solvents; practically insoluble in water | Solvent choice affects laboratory handling |
| Typical storage | -20 °C, desiccated, protected from light | Common condition for research samples |
| Analytical method | Liquid chromatography–tandem mass spectrometry (LC-MS/MS) | Used for identification and quantification in biological or product samples |
| Common synonyms | GW501516, GW-501516, GSK-516, Endurobol | Names found in research and anti-doping literature |
| Regulatory status | Unapproved therapeutic; prohibited in competitive sport | Status can vary by country and context |
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Angiomas: These are vascular tumours, including haemangioma, lymphangioma, venus varix. Angiomas are difficult to classify as previously they were considered hamartomas, benign tumour-like malformations but there is debate if they are developmental abnormality, true benign tumour or hamartoma, or can be either. Haemangiomas are common in the oral mucosa but can occur in other structures such as salivary glands, and can be congenital or develop in childhood. Congenital lesions can resolve spontaneously (involute) but those that develop later usually continue to slowly grow. They are usually dark red-purple or blue, soft, sometimes fluctuant and painless. They commonly blanch on pressure. Usually solitary, they can occur as part of syndromes such as Sturge–Weber syndrome affecting the trigeminal nerve. They are at risk of trauma with subsequent excessive bleeding, thrombosis or calcification. Lymphangiomas are far less common in the oral mucosa, usually appearing on the tongue, less commonly the lip at birth or in infancy. They are colourless to pale pink and may be nodular projections or resemble "frog spawn" domes. They can cause macroglossia (enlargement of the tongue). Venous varix, like varicose vein, usually appear in older people on the lower lip as a blue-purple lump.
== History == In 1962, Stanozolol was brought to market in the US by Winthrop under the tradename "Winstrol" and in Europe by Winthrop's partner, Bayer, under the name "Stromba". Also in 1962, the Kefauver Harris Amendment was passed, amending the Federal Food, Drug, and Cosmetic Act to require drug manufacturers to provide proof of the effectiveness of their drugs before approval. The FDA implemented its Drug Efficacy Study Implementation (DESI) program to study and regulate drugs, including stanozolol, that had been introduced prior to the amendment. The DESI program was intended to classify all pre-1962 drugs that were already on the market as effective, ineffective, or needing further study. The FDA enlisted the National Research Council of the National Academy of Sciences to evaluate publications on relevant drugs under the DESI program. In June 1970 the FDA announced its conclusions on the effectiveness of certain AAS, including stanozolol, based on the NAS/NRC reports made under DESI. The drugs were classified as probably effective as adjunctive therapy in the treatment of senile and postmenopausal osteoporosis but only as an adjunct, and in pituitary dwarfism (with a specific caveat for dwarfism, "until growth hormone is more available"), and as lacking substantial evidence of effectiveness for several other indications.
== Alkaline collagen swelling == The presence of calcium hydroxide results in the alkaline swelling of skin. The result is an influx of water into the hide/skin, and a marked increase in fibre diameter and fibre shortening. The thickness of the skin increases, but the surface area of the pelt decreases. The weight increase, owing to the uptake of water, results in a doubling of the hide/skin weight. However, this weight also needs to take into consideration that proteins (especially the hair) have been removed, and the fleshing operation is often performed after liming.
Wolverine is a superhero appearing in American comic books published by Marvel Comics. The character first appeared in the comic book The Incredible Hulk #180 (1974) and is best known as a member of the superhero team, the X-Men. Wolverine is the alias of James "Logan" Howlett, a mutant born in Canada in the late 19th century. He possesses a range of superpowers including highly advanced self-healing abilities, a significantly prolonged lifespan, animal-keen senses, and retractable claws. His skeleton is reinforced with the unbreakable fictional metal adamantium, which he acquired after becoming an unwilling test subject in the Weapon X super soldier program. Wolverine is commonly depicted as a gruff loner susceptible to animalistic "berserker rages" who struggles to reconcile his humanity with his wild nature. Initially portrayed as a Canadian government-sanctioned superhero and a rival of the Hulk, Wolverine was later recruited by Charles Xavier to join his second team of X-Men and has since been one of their key members. Since joining the X-Men, Wolverine has built strong relationships with many of his teammates, being close friends with Nightcrawler, Colossus, and Storm, with whom he also has an on-again, off-again relationship. Wolverine has a complicated but strong friendship with Scott Summers / Cyclops, who he initially views as a rival but has since become one of his most trusted allies on the team. When he first joined the X-Men, Wolverine harbored romantic feelings for Jean Grey, but ultimately chose to reject her out of respect for her and Scott's marriage.
Sources: en.wikipedia.org
=== Liquid-liquid equilibrium calculations === In order to calculate the phase equilibrium, it is necessary to use a thermodynamic model such as NRTL, UNIQUAC, etc. The corresponding parameters of these models can be obtained from literature (e.g. Dechema Chemistry Data Series, Dortmund Data Bank, etc.) or by a correlation process of experimental data.
This is a list of published International Organization for Standardization (ISO) standards and other deliverables. For a complete and up-to-date list of all the ISO standards, see the ISO catalogue. The standards are protected by copyright and most of them must be purchased. However, about 300 of the standards produced by ISO and IEC's Joint Technical Committee 1 (JTC 1) have been made freely and publicly available.
=== Biosphere === Methanogenesis is a form of anaerobic respiration used by microbes, and microbial methanogenesis can occur in deep subsurface, marine sediments, freshwater bodies, etc. It appears that methane from deep subsurface and marine sediment is generally in internal isotopic equilibrium., while freshwater microbial methanogenesis expresses large kinetic isotope effect on methane clumped isotope composition. There are two possible explanations for this variance: firstly, substrate limitation may enhance the reversibility of methanogenesis, thus allowing methane to achieve internal isotopic equilibrium via rapid hydrogen exchange with water; secondly, activation of C-H bonds during anaerobic oxidation precedes reversibly such that C-H bonds are broken and reformed faster than the net rate of methane consumption and methane can be reequilibrated.
Sources: en.wikipedia.org
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.
No. It is not an anabolic-androgenic steroid; it is a synthetic PPARδ agonist. Because it is banned in sport, it is sometimes grouped with doping agents even though its chemical class differs from steroids.
Human data are limited and development was discontinued, so major effects and long-term risks are not well characterized. Some early studies examined metabolic markers, but they do not provide a basis for unsupervised use.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.